Jiudian Pharmaceutical (300705): As long as the pattern is good, the growth is fine
Jiudian Pharmaceutical (300705): The profit side maintained rapid growth and the sales expense ratio declined significantly
Jiudian Pharmaceutical (300705): Performance is in line with expectations, and the cost rate continues to improve
Jiudian Pharmaceutical (300705): Significant improvement in sales expenses ratio continues to move towards a platform-based company
Jiudian Pharmaceutical (300705): Performance exceeds expectations, has rich research pipelines, and strong long-term growth momentum
Jiudian Pharmaceutical (300705): Significant optimization of sales expenses ratio, Q2 performance exceeded expectations under a high base
Jiudian Pharmaceutical (300705): High profit side growth and continuous expansion of the product matrix in the field of dermal administration
Jiudian Pharmaceutical (300705): Continued rapid growth under a high base, profit margins continued to rise
Jiudian Pharmaceutical (300705): Sales Expense Optimization Performance Continues to Grow High
Jiudian Pharmaceutical (300705): Gel patches enable development and blossom more, and the future can be expected
CICC Starts Hunan Jiudian Pharmaceutical at Outperform With 32 Yuan Price Target
Jiudian Pharmaceutical (300705): Chemical paste platform-type leader creates a product matrix for transdermal drug delivery
Jiudian Pharmaceutical (300705): A leading integrated strategy for chemical, gel, and paste can be expected in the future
Jiudian Pharmaceutical (300705) Company Brief Review Report: Rapid Growth in Topical Formulations, Steady Improvement in Profitability
Jiudian Pharmaceutical (300705): Continued release of core products, further improving operational efficiency
Jiudian Pharmaceutical (300705): Promoting the construction of a transdermal drug delivery product echelon, it is expected to blossom more in and outside the hospital
Huafu Securities released a research report on April 28 stating that it gave Jiudian Pharmaceutical (300705.SZ) a purchase rating, and the target price was 44.9 yuan. The main reasons for the rating include: 1) the steady growth of various businesses in 2
Huayuan Securities released a research report on April 24 stating that it gave Jiudian Pharmaceutical (300705.SZ) a purchase rating. The main reasons for the rating include: 1) China has more than 300 million chronic pain patients, and gel patches have si
Jiudian Pharmaceutical (300705): Outstanding performance, rich cream pipeline, strong growth momentum
Jiudian Pharmaceutical (300705): a leading platform-based paste company with rapid growth
No Data
No Data